Skip to main content
MB

Michael B. Chancellor

Biography​

Michael B. Chancellor is a professor of urology at Oakland University William Beaumont School of Medicine.12 Chancellor earned a medical degree at the Medical College of Wisconsin and completed urology residency at the University of Michigan.3 Chancellor completed a fellowship in neurourology and female urology at Columbia University College of Physicians and Surgeons and worked with research mentor Jerry Blaivas there.34

Contributions​

Chancellor's cited work examines botulinum toxin for overactive bladder and other voiding disorders, including bladder instillation of liposome-encapsulated onabotulinumtoxinA and studies of urothelial response.56789

Cited on WARWIKI

18 publications with Michael B. Chancellor as a listed author are cited on WARWIKI, ordered by the number of pages that cite them. Papers whose author list is shortened to "et al." before this name are not included.

  1. da Silva CM, Chancellor MB, Smith CP, Cruz F. "Use of botulinum toxin for genitourinary conditions: what is the evidence?" Toxicon. 2015;107(Pt A):141–147. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct) · Intradetrusor OnabotulinumtoxinA
  2. Chancellor MB, Watanabe T, Rivas DA, et al. "Gracilis Urethral Myoplasty: Preliminary Experience Using an Autologous Urinary Sphincter for Post-Prostatectomy Incontinence." J Urol. 1997;158(4):1372–1375. doi
    Cited on: The Leg & Thigh · Gracilis Flap
  3. Chancellor MB, Erhard MJ, Kiilholma PJ, Karasick S, Rivas DA. Functional urethral closure with pubovaginal sling for destroyed female urethra after long-term urethral catheterization. Urology. 1994;43(4):499-505. doi
    Cited on: Bladder Neck Closure · Ileovesicostomy
  4. Chancellor MB, Lucioni A, Staskin D. Oxybutynin-associated cognitive impairment: evidence and implications for overactive bladder treatment. Urology. 2024;186:123–129. doi
    Cited on: Anticholinergic / Antimuscarinic Agents
  5. Shen YC, Tyagi P, Lee WC, Chancellor M, Chuang YC. "Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo." Sci Rep. 2021;11(1):7558. doi
    Cited on: Low-Intensity Extracorporeal Shockwave Therapy (Li-ESWT)
  6. Chuang YC, Meng E, Chancellor M, Kuo HC. "Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndrome — a prospective, multicenter, randomized, double-blind, placebo-controlled study." Neurourol Urodyn. 2020;39(5):1505–1514. doi
    Cited on: Low-Intensity Extracorporeal Shockwave Therapy (Li-ESWT)
  7. Chancellor MB, Bartolone SN, DeVries EM, et al. "New technology assessment and current and upcoming therapies for underactive bladder." Neurourol Urodyn. 2018;37(8):2932–7. doi
    Cited on: Bladder Scanner
  8. Tyagi P, Kashyap M, Yoshimura N, Chancellor M, Chermansky CJ. "Past, present and future of chemodenervation with botulinum toxin in the treatment of overactive bladder." J Urol. 2017;197(4):982–990. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct)
  9. Chermansky CJ, Chancellor MB. "Use of botulinum toxin in urologic diseases." Urology. 2016;91:21–32. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct)
  10. Liu HT, Chen SH, Chancellor MB, Kuo HC. "Presence of cleaved synaptosomal-associated protein-25 and decrease of purinergic receptors P2X3 in the bladder urothelium influence efficacy of botulinum toxin treatment for overactive bladder syndrome." PLoS One. 2015;10(8):e0134803. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct)
  11. Chuang YC, Kaufmann JH, Chancellor DD, Chancellor MB, Kuo HC. "Bladder instillation of liposome-encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial." J Urol. 2014;192(6):1743–1749. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct)
  12. Kuo HC, Liu HT, Chuang YC, Birder LA, Chancellor MB. "Pilot study of liposome-encapsulated onabotulinumtoxinA for patients with overactive bladder: a single-center study." Eur Urol. 2014;65(6):1117–1124. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct)

Footnotes​

  1. Corewell Health Clinical Faculty. Oakland University. Accessed October 2026. ↩

  2. AUA 2022 Annual Meeting. Accessed October 2026. ↩

  3. ICS. Prof Michael Chancellor. Accessed October 2026. ↩ ↩2

  4. Individualizing Urinary Incontinence Treatment—Evolving Research Questions to Reserach Plans: Executive Summar. Accessed October 2026. ↩

  5. da Silva CM, Chancellor MB, Smith CP, Cruz F. "Use of botulinum toxin for genitourinary conditions: what is the evidence?" Toxicon. 2015;107(Pt A):141–147. doi:10.1016/j.toxicon.2015.07.333 ↩

  6. Chancellor MB, Elovic E, Esquenazi A, et al. "Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions." Toxicon. 2013;67:129–140. doi:10.1016/j.toxicon.2013.01.020 ↩

  7. Chermansky CJ, Chancellor MB. "Use of botulinum toxin in urologic diseases." Urology. 2016;91:21–32. doi:10.1016/j.urology.2015.12.049 ↩

  8. Tyagi P, Kashyap M, Yoshimura N, Chancellor M, Chermansky CJ. "Past, present and future of chemodenervation with botulinum toxin in the treatment of overactive bladder." J Urol. 2017;197(4):982–990. doi:10.1016/j.juro.2016.11.092 ↩

  9. Chuang YC, Kaufmann JH, Chancellor DD, Chancellor MB, Kuo HC. "Bladder instillation of liposome-encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial." J Urol. 2014;192(6):1743–1749. doi:10.1016/j.juro.2014.07.008 ↩